Regulatory T cells and cytotoxic T cells close to the epithelial-stromal interface are associated with a favorable prognosis.
epithelial–stromal interface
rectal cancer
regulatory T cells
spatial distribution
cytotoxic T cells
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
10
2019
revised:
09
01
2020
accepted:
29
02
2020
entrez:
5
5
2020
pubmed:
5
5
2020
medline:
5
5
2020
Statut:
epublish
Résumé
Cytotoxic T cells and regulatory T cells play a crucial role in the outcome of cancer patients. Besides the density of these cells, it was shown recently that the spatial distribution is equally important. Here, we specifically analyzed the spatial distribution of these T cell subtypes at the epithelial-stromal interface in a rectal cancer cohort and its relevance for prognosis. We studied a cohort of 191 patients with advanced rectal cancer treated by radiochemotherapy (RCT). Tissue microarrays were immunohistochemical double-stained by FoxP3+ and CD+. Cell densities were analyzed in the stromal and epithelial compartment. Additionally, an image analysis software calculated the distances of lymphocytes to the epithelial-stromal interface (ESI). CD8+ and FoxP3+ cell counts decreased clearly after RCT with the decrease of FoxP3+ being more pronounced than of CD8+ cells. In the invasive front, short distances of the ESI to CD8+ and to FoxP3+ cells were associated with improved overall survival. Cell counts in the stromal compartment had no influence on prognosis. No correlation between stromal and epithelial lymphocyte densities was observed. The distance of epithelial-stromal interface to CD8+ and FoxP3+ cells was more accurate in predicting prognosis in the stromal compartment of rectal cancer patients than mere cell counts and could thereby be means of better stratifying patients for therapy. This observation will have to be validated in future prospective studies with regard to other tumor entities and its implications for the responsiveness of tumors to new therapeutic modalities.
Identifiants
pubmed: 32363115
doi: 10.1080/2162402X.2020.1746149
pii: 1746149
pmc: PMC7185207
doi:
Substances chimiques
Forkhead Transcription Factors
0
Types de publication
Journal Article
Langues
eng
Pagination
1746149Informations de copyright
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
J Immunother. 2010 May;33(4):435-41
pubmed: 20386463
J Clin Oncol. 2009 Jan 10;27(2):186-92
pubmed: 19064967
PLoS One. 2011;6(7):e22047
pubmed: 21818290
Nat Rev Immunol. 2010 Jul;10(7):490-500
pubmed: 20559327
Cancer Immunol Immunother. 2014 Feb;63(2):111-9
pubmed: 24170095
Lab Invest. 2015 Apr;95(4):377-84
pubmed: 25599534
Oncotarget. 2016 Sep 13;7(37):60383-60394
pubmed: 27494875
Oncoimmunology. 2017 Feb 23;6(3):e1286436
pubmed: 28405518
Cancers (Basel). 2019 Sep 19;11(9):
pubmed: 31546872
Oncoimmunology. 2016 Jan 13;5(5):e1127494
pubmed: 27467940
Strahlenther Onkol. 2019 Feb;195(2):103-112
pubmed: 30191285
Nat Commun. 2017 Apr 27;8:15095
pubmed: 28447602
Strahlenther Onkol. 2018 Nov;194(11):991-1006
pubmed: 30069738
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3967-72
pubmed: 17360461
Cancer Res. 2001 Jul 1;61(13):5132-6
pubmed: 11431351
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259